DK0724583T3 - Pyridazino-quinolin-forbindelser - Google Patents

Pyridazino-quinolin-forbindelser

Info

Publication number
DK0724583T3
DK0724583T3 DK94930275T DK94930275T DK0724583T3 DK 0724583 T3 DK0724583 T3 DK 0724583T3 DK 94930275 T DK94930275 T DK 94930275T DK 94930275 T DK94930275 T DK 94930275T DK 0724583 T3 DK0724583 T3 DK 0724583T3
Authority
DK
Denmark
Prior art keywords
phenyl
deriv
substd
opt
furyl
Prior art date
Application number
DK94930275T
Other languages
Danish (da)
English (en)
Inventor
Thomas Michael Bare
Richard Bruce Sparks
James Roy Empfield
Timothy Wayne Davenport
Jeffrey Alan Mckinney
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB939321854A external-priority patent/GB9321854D0/en
Priority claimed from GB9417171A external-priority patent/GB9417171D0/en
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Application granted granted Critical
Publication of DK0724583T3 publication Critical patent/DK0724583T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D215/00Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/54Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
    • C07D215/56Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3 with oxygen atoms in position 4

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Saccharide Compounds (AREA)
DK94930275T 1993-10-22 1994-10-20 Pyridazino-quinolin-forbindelser DK0724583T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB939321854A GB9321854D0 (en) 1993-10-22 1993-10-22 Pyridazino quinoline compounds
GB9417171A GB9417171D0 (en) 1994-08-25 1994-08-25 Pyridazino quinoline compounds
PCT/GB1994/002295 WO1995011244A1 (en) 1993-10-22 1994-10-20 Pyridazino quinoline compounds

Publications (1)

Publication Number Publication Date
DK0724583T3 true DK0724583T3 (da) 2001-03-05

Family

ID=26303731

Family Applications (2)

Application Number Title Priority Date Filing Date
DK94930275T DK0724583T3 (da) 1993-10-22 1994-10-20 Pyridazino-quinolin-forbindelser
DK00101917T DK1004582T3 (da) 1993-10-22 1994-10-20 Pyradazinoquinolinforbindelser

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK00101917T DK1004582T3 (da) 1993-10-22 1994-10-20 Pyradazinoquinolinforbindelser

Country Status (30)

Country Link
US (3) US5744471A (xx)
EP (2) EP0724583B1 (xx)
JP (1) JP3583132B2 (xx)
KR (1) KR100261209B1 (xx)
CN (1) CN1053189C (xx)
AT (2) ATE295846T1 (xx)
AU (2) AU688393B2 (xx)
CA (1) CA2171332A1 (xx)
CZ (1) CZ292311B6 (xx)
DE (2) DE69434380T2 (xx)
DK (2) DK0724583T3 (xx)
ES (2) ES2154686T3 (xx)
FI (2) FI113865B (xx)
GB (1) GB9420590D0 (xx)
GR (1) GR3035080T3 (xx)
HK (1) HK1013997A1 (xx)
HU (1) HUT74161A (xx)
IL (1) IL111266A (xx)
MY (2) MY124316A (xx)
NO (1) NO306995B1 (xx)
NZ (2) NZ329303A (xx)
PL (1) PL180679B1 (xx)
PT (2) PT1004582E (xx)
RU (1) RU2168511C2 (xx)
SG (2) SG92630A1 (xx)
SI (2) SI1004582T1 (xx)
SK (1) SK282491B6 (xx)
TW (1) TW406082B (xx)
UA (1) UA60291C2 (xx)
WO (1) WO1995011244A1 (xx)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL111266A (en) * 1993-10-22 2002-03-10 Zeneca Ltd 2-HETEROARYL OR 2-ARYLPYRIDAZINO [4,5-b] QUINOLINE - 1, 10 - DIONES, THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
GB9422894D0 (en) * 1994-11-12 1995-01-04 Zeneca Ltd Pyridazino quinoline compounds
US6214826B1 (en) 1994-11-12 2001-04-10 Zeneca Limited Pyridazino quinoline compounds
GB9507318D0 (en) * 1995-04-07 1995-05-31 Zeneca Ltd Alpha substituted pyridazino quinoline compounds
SI1244662T1 (xx) * 1999-12-23 2005-08-31 Astrazeneca Ab
WO2001047923A1 (en) * 1999-12-23 2001-07-05 Astrazeneca Ab Compounds and methods for the treatment of pain
US20030176435A1 (en) * 2002-12-17 2003-09-18 Brown Dean Gordon Compounds and methods for the treatment of pain
US6730675B2 (en) 1999-12-23 2004-05-04 Astrazeneca Ab Compounds and methods for the treatment of pain
EP1244664A1 (en) * 1999-12-23 2002-10-02 AstraZeneca AB Compounds and methods for the treatment of pain
EE200200348A (et) * 1999-12-23 2003-08-15 Astrazeneca Ab Ravimkoostis kasutamiseks valu ravis
PT1244662E (pt) * 1999-12-23 2005-07-29 Astrazeneca Ab Derivado de piridazinoquinolina e metodo para o tratamento da dor
US6787547B2 (en) 1999-12-23 2004-09-07 Astrazeneca Ab Compound and method for the treatment of pain
EP1244453A1 (en) * 1999-12-23 2002-10-02 AstraZeneca AB Method and composition for the treatment of pain
EP1244661A1 (en) * 1999-12-23 2002-10-02 AstraZeneca AB Compounds and methods for the treatment of pain
US6943165B2 (en) * 1999-12-23 2005-09-13 Astrazeneca Ab Compound and method for the treatment of pain
WO2001047924A1 (en) * 1999-12-23 2001-07-05 Astrazeneca Ab Methods and compositions for the treatment of pain
US6403818B1 (en) 2000-02-28 2002-06-11 Eisai Co., Ltd. Process for producing α-hydroxy-carbonyl compound
AU2002214441A1 (en) * 2000-09-29 2002-04-08 Astrazeneca Ab 1,2,5,10-tetrahydropyridazino(4,5-b)quinoline-1,10-diones and their use for the treatment of pain
ES2263661T3 (es) * 2000-09-29 2006-12-16 Astrazeneca Ab 1,2,5,10-tetrahidropiridazino(4,5-b)quinolin-1,10-dionas y su uso para el tratamiento del dolor.
DE60121978D1 (de) 2000-09-29 2006-09-14 Astrazeneca Ab 7-CHLOR-4-HYDROXY-2-(2-PYRIDYLETHYL)-1,2,5,10-TETRAHYDROPYRIDAZINOi4,5-BöCHINOLIN-1,10-DIONE UND IHRE VERWENDUNG ZUR BEHANDLUNG VON SCHMERZEN
AU2001292500A1 (en) 2000-09-29 2002-04-08 Astrazeneca Ab 1,2,5,10-tetrahydropyridazino(4,5-b)quinoline-1,10-diones and their use for the treatment of pain
US20100074949A1 (en) 2008-08-13 2010-03-25 William Rowe Pharmaceutical composition and administration thereof
EP1390349B1 (en) * 2001-05-31 2012-07-25 Sanofi Aminoquinoline and aminopyridine derivatives and their use as adenosine a3 ligands
WO2005012309A1 (en) 2003-08-04 2005-02-10 Valery Khazhmuratovich Zhilov Cyclic bioisosters of purine system derivatives and a pharmaceutical composition based thereon
CN101891680B (zh) 2004-06-24 2014-10-29 沃泰克斯药物股份有限公司 Atp-结合弹夹转运蛋白的调控剂
US8354427B2 (en) 2004-06-24 2013-01-15 Vertex Pharmaceutical Incorporated Modulators of ATP-binding cassette transporters
EP1979367A2 (en) * 2005-12-24 2008-10-15 Vertex Pharmaceuticals Incorporated Quinolin-4-one derivatives as modulators of abc transporters
ES2624554T3 (es) 2005-12-28 2017-07-14 Vertex Pharmaceuticals Incorporated Formas sólidas de n- [2,4 - bis (1,1 - dimetiletil) - 5 - hidroxifenil] - 1,4 - dihidro - 4 - oxoquinolina - 3 - carboxamida
EP2408750B1 (en) 2009-03-20 2015-08-26 Vertex Pharmaceuticals Incorporated Process for making modulators of cystic fibrosis transmembrane conductance regulator
US8802700B2 (en) 2010-12-10 2014-08-12 Vertex Pharmaceuticals Incorporated Modulators of ATP-Binding Cassette transporters
NZ629199A (en) 2012-02-27 2017-01-27 Vertex Pharma Pharmaceutical compositions comprising a solid dispersion of n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide
CA2963945C (en) 2014-10-07 2023-01-10 Vertex Pharmaceuticals Incorporated Co-crystals of modulators of cystic fibrosis transmembrane conductance regulator

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9109972D0 (en) * 1991-05-09 1991-07-03 Ici Plc Therapeutic compounds
GB9208511D0 (en) * 1991-05-09 1992-06-03 Ici Plc Compounds
IL111266A (en) * 1993-10-22 2002-03-10 Zeneca Ltd 2-HETEROARYL OR 2-ARYLPYRIDAZINO [4,5-b] QUINOLINE - 1, 10 - DIONES, THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
GB9422894D0 (en) * 1994-11-12 1995-01-04 Zeneca Ltd Pyridazino quinoline compounds
GB9507318D0 (en) * 1995-04-07 1995-05-31 Zeneca Ltd Alpha substituted pyridazino quinoline compounds

Also Published As

Publication number Publication date
FI113865B (fi) 2004-06-30
AU688393B2 (en) 1998-03-12
ES2241513T3 (es) 2005-11-01
DK1004582T3 (da) 2005-08-15
FI961696A (fi) 1996-04-18
AU721139B2 (en) 2000-06-22
ATE198072T1 (de) 2000-12-15
EP1004582B1 (en) 2005-05-18
AU6899998A (en) 1998-07-30
SI1004582T1 (xx) 2005-08-31
CZ113896A3 (en) 1996-09-11
CN1053189C (zh) 2000-06-07
GR3035080T3 (en) 2001-03-30
CZ292311B6 (cs) 2003-09-17
DE69426422T2 (de) 2001-05-10
PL180679B1 (en) 2001-03-30
AU7944094A (en) 1995-05-08
MY124316A (en) 2006-06-30
NO306995B1 (no) 2000-01-24
NZ275472A (en) 1998-03-25
KR100261209B1 (ko) 2000-09-01
ES2154686T3 (es) 2001-04-16
PL314041A1 (en) 1996-08-05
PT1004582E (pt) 2005-09-30
TW406082B (en) 2000-09-21
SG92630A1 (en) 2002-11-19
HUT74161A (en) 1996-11-28
IL111266A (en) 2002-03-10
SK282491B6 (sk) 2002-02-05
FI114916B (fi) 2005-01-31
JP3583132B2 (ja) 2004-10-27
ATE295846T1 (de) 2005-06-15
CA2171332A1 (en) 1995-04-27
NO961584L (no) 1996-04-19
SI0724583T1 (en) 2001-04-30
RU2168511C2 (ru) 2001-06-10
NO961584D0 (no) 1996-04-19
EP0724583B1 (en) 2000-12-13
CN1138332A (zh) 1996-12-18
DE69434380T2 (de) 2006-05-04
DE69426422D1 (de) 2001-01-18
DE69434380D1 (de) 2005-06-23
FI961696A0 (fi) 1996-04-18
WO1995011244A1 (en) 1995-04-27
US6103721A (en) 2000-08-15
EP1004582A3 (en) 2000-08-30
SG59971A1 (en) 1999-02-22
NZ329303A (en) 2000-01-28
FI970907A0 (fi) 1997-03-03
FI970907A (fi) 1997-03-03
HK1013997A1 (en) 1999-09-17
GB9420590D0 (en) 1994-11-30
MY132875A (en) 2007-10-31
PT724583E (pt) 2001-03-30
US5744471A (en) 1998-04-28
EP1004582A2 (en) 2000-05-31
HU9600889D0 (en) 1996-06-28
UA60291C2 (uk) 2003-10-15
EP0724583A1 (en) 1996-08-07
IL111266A0 (en) 1994-12-29
US6232313B1 (en) 2001-05-15
SK50496A3 (en) 1997-03-05
JPH09504519A (ja) 1997-05-06

Similar Documents

Publication Publication Date Title
DK0724583T3 (da) Pyridazino-quinolin-forbindelser
ATE237596T1 (de) Chinazolinderivate und deren verwendung als vegf hemmer
ES2166954T3 (es) Derivados de 1-fenilpirazol y su uso como agentes parasiticidas.
ES8600288A1 (es) Un procedimiento para la preparacion de derivados de quinolina.
EA199900927A1 (ru) Трициклические соединения
ATE148700T1 (de) Tricyclische heterocyclen als pge2-antagonisten
ATE132136T1 (de) Antitumor anthracenderivate
ATE162191T1 (de) Azanoradamantane
ES2063177T3 (es) Antagonistas de calcio.
ATE404558T1 (de) Antimikrobielle 4-oxochinolizinverbindungen, die als teilstruktur ein 2-pyridonskelett aufweisen
TNSN87066A1 (fr) Derives propargyloxybenzenes leur preparation et compositions fongicides les contenant